Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma

DSpace/Manakin Repository

Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma

Citable link to this page

 

 
Title: Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma
Author: Wong, E T; Lok, E; Gautam, S; Swanson, K D

Note: Order does not necessarily reflect citation order of authors.

Citation: Wong, E T, E Lok, S Gautam, and K D Swanson. 2015. “Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma.” British Journal of Cancer 113 (2): 232-241. doi:10.1038/bjc.2015.238. http://dx.doi.org/10.1038/bjc.2015.238.
Full Text & Related Files:
Abstract: Background: Patients with recurrent glioblastoma have a poor outcome. Data from the phase III registration trial comparing tumour-treating alternating electric fields (TTFields) vs chemotherapy provided a unique opportunity to study dexamethasone effects on patient outcome unencumbered by the confounding immune and myeloablative side effects of chemotherapy. Methods: Using an unsupervised binary partitioning algorithm, we segregated both cohorts of the trial based on the dexamethasone dose that yielded the greatest statistical difference in overall survival (OS). The results were validated in a separate cohort treated in a single institution with TTFields and their T lymphocytes were correlated with OS. Results: Patients who used dexamethasone doses >4.1 mg per day had a significant reduction in OS when compared with those who used ⩽4.1 mg per day, 4.8 vs 11.0 months respectively (χ2=34.6, P<0.0001) in the TTField-treated cohort and 6.0 vs 8.9 months respectively (χ2=10.0, P<0.0015) in the chemotherapy-treated cohort. In a single institution validation cohort treated with TTFields, the median OS of patients who used dexamethasone >4.1 mg per day was 3.2 months compared with those who used ⩽4.1 mg per day was 8.7 months (χ2=11.1, P=0.0009). There was a significant correlation between OS and T-lymphocyte counts. Conclusions: Dexamethasone exerted profound effects on both TTFields and chemotherapy efficacy resulting in lower patient OS. Therefore, global immunosuppression by dexamethasone likely interferes with immune functions that are necessary for the treatment of glioblastoma.
Published Version: doi:10.1038/bjc.2015.238
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506397/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:17820880
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters